CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-Label Phase II Trial of Fulvestrant And Neratinib in Previously Treated HRPositive, HER2-Negative Metastatic Breast Cancer Subjects Assessed With a Test Measuring Live Cell HER2 Signaling Function

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04901299
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:02.887476+00:00
Published At: 2023-08-01T00:00:00+00:00
Record Updated At: 2023-08-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Stage IV (Metastatic) Breast Cancer", "Metastatic Breast Cancer", "ER Positive Breast Cancer", "PR-Positive Breast Cancer", "HER2-negative Breast Cancer", "Invasive Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-08-01"
protocolSection.identificationModule.nctId: "NCT04901299"
protocolSection.identificationModule.officialTitle: "An Open-Label Phase II Trial of Fulvestrant And Neratinib in Previously Treated HRPositive, HER2-Negative Metastatic Breast Cancer Subjects Assessed With a Test Measuring Live Cell HER2 Signaling Function"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.